KPTI News and Press, Karyopharm Therapeutics Inc. From 09/15/21

Karyopharm Therapeutics has been on my watch list for several years. Sadly, my buy conditions never manifested for me to establish a position. Now I am looking for an entry. I believe Karyopharm’s current valuation along with its upside potential will eventually bring in some b...

Karyopharm Therapeutics (KPTI -8.0%) lost more than 20% on Thursday, the most since February 2019 after the company’s Q2 2021 revenue lagged analyst expectations. Driven by the lead compound XPOVIO (selinexor), the product revenue rose ~8.5% YoY to $20.2M compared to ~$18.6M in Q2 2020...

Image source: The Motley Fool. Karyopharm Therapeutics inc (NASDAQ: KPTI) Q2 2021 Earnings Call Aug 5, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics inc (KPTI) Q2 2021 Earnings Call Transcr...

Karyopharm Therapeutics Inc. (KPTI) Q2 2021 Earnings Conference Call August 5, 2021 8:30 AM ET Company Participants Joe Rayne - Argot Partners Richard Paulson - President & Chief Executive Officer Sohanya Cheng - Senior Vice President-Sales & Commercial Operations Jatin Shah - Chief M...

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Karyopharm Therapeutics Inc. 2021 Q2 - Results - Earnings Call Presentation

Gainers: Profound Medical (NASDAQ:PROF) +28%, STAAR Surgical (NASDAQ:STAA) +19%, AdaptHealth (NASDAQ:AHCO) +17%, Flora Growth (NASDAQ:FLGC) +16%, Invacare (NYSE:IVC) +15%. Losers: Inogen (NASDAQ:INGN) -32%, Karyopharm Therapeutics (NASDAQ:KPTI) ...

Fastly FSLY -23% on Q2 earnings release  Karyopharm Therapeutics KPTI -18% on Q2 earnings release  Fiverr International FVRR -17% on Q2 earnings release Etsy ETSY -13% on Q2 earnings release Maxar Technologies MAXR -13% on Q2 earning...

Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results -- Achieved Second Quarter 2021 XPOVIO® (selinexor) Net Product Revenues of $20.2 Million and $41.9 Million YTD, Up 8% Versus Second Quarter 2020 and Up 21% Versus First Half of 2020 -- -- ...

Karyopharm Therapeutics' (NASDAQ:KPTI) partner Antengene announces that through a priority review process, the South Korean Ministry of Food and Drug Safety has approved its New Drug Application (NDA) for the Orphan Drug-designated oral inhibitor of XPO1, selinexor (XPOVIO...

Karyopharm to Report Second Quarter 2021 Financial Results on August 5, 2021 -- Conference Call Scheduled for Thursday, August 5, 2021, at 8:30 a.m. ET -- PR Newswire NEWTON, Mass. , July 29, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPT...